| N | Training group | Test group | p Value |
---|---|---|---|---|
Total, n | 465 | 233(50.1%) | 232(49.9%) | Â |
Mean age, y |  | 59.61 ± 11.03 | 59.84 ± 11.54 | 0.822 |
Stage | 0.939 | |||
 I | 12(2.6%) | 7(3.0%) | 5(2.2%) |  |
 II | 17(3.7%) | 8(3.4%) | 9(3.9%) |  |
 III | 369(79.4%) | 185(79.4%) | 184(79.3%) |  |
 IV | 67(14.4%) | 33(14.2%) | 34(14.7%) |  |
Primary therapy outcome | 0.773 | |||
 Complete remission | 270(58.1%) | 140(60.1%) | 130(56.0%) |  |
 Partial remission | 51(11.0%) | 25(10.7%) | 26(11.2%) |  |
 Progressive disease | 32(6.9%) | 14(6.0%) | 18(7.8%) |  |
 Stable disease | 27(5.8%) | 15(6.4%) | 12(5.2%) |  |
 Unknown | 85(18.3%) | 39(16.7%) | 46(19.8%) |  |
Tumour residual | 0.894 | |||
 No macroscopic disease | 100(21.5%) | 50(21.5%) | 50(21.6%) |  |
 1–10 mm | 209(44.9%) | 100(42.9%) | 109(47.0%) |  |
 11–20 mm | 28(6.0%) | 15(6.4%) | 13(5.6%) |  |
 > 20 mm | 89(19.1%) | 48(20.6%) | 41(17.7%) |  |
 Unknown | 39(8.4%) | 20(8.6%) | 19(8.2%) |  |
Venous invasion | 0.296 | |||
 No | 53(11.4%) | 29(12.4%) | 24(10.3%) |  |
 Yes | 72(15.5%) | 41(17.6%) | 31(13.4%) |  |
 Unknown | 340(73.1%) | 163(70.0%) | 177(76.3%) |  |
Survival status | 0.365 | |||
 Alive | 188(40.4%) | 99(42.5%) | 89(38.4%) |  |
 Dead | 277(59.6%) | 134(57.5%) | 143(61.6%) |  |
Lymphatic invasion | 0.795 | |||
 No | 62(13.3%) | 33(14.2%) | 29(12.5%) |  |
 Yes | 117(25.2%) | 60(25.8%) | 57(24.6%) |  |
 Unknown | 286(61.5%) | 140(60.1%) | 146(62.9%) |  |